可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacot herapy in women: a statement for healthcare professionals from the American Heart Association[J]. Circulation, 2005, 111(7):940-953.
[2] 杜宗雷,丛培玲,孙晓斐,等.经皮直接冠状动脉介入治疗ST段抬高型心肌梗死患者近中期预后的相关因素[J]. 心脏杂志, 2007, 19(4):460-463.
[3] 韩雅玲,李成洋,王效增,等. 多支冠状动脉病变患者1911例PCI二年疗效[J]. 心脏杂志, 2007, 19(3):302-305.
[4] 周志文,石蓓,樊启财,等. 急诊PCI和延期PCI患者QT离散度对比分析[J].心脏杂志, 2007, 19(3):323-325.
[5] 纪辉,金丽娟,李学奇,等. 那屈肝素在冠状动脉介入治疗中的效果和安全性[J].心脏杂志, 2007, 19(1):52-56.
[6] Argulian E, Patel AD, Abramson JL, et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions[J]. Am J Cardiol, 2006, 98(1):48-53.
[7] Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women:the national heart,lung,and blood institute-sponsored women’s ischemia syndrome evaluation(WISE)[J]. Circulation, 2004, 109(6):726-732.
[8] von Mering GO, Arant CB, Wessel TR, et al.Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the national heart, lung, and blood institutesponsored women’s ischemia syndrome evaluation (WISE)[J]. Circulation, 2004, 109(6):722-725.